Mesenchymal stem cell like (MSCl) cells generated from human embryonic stem cells support pluripotent cell growth

Biochemical and Biophysical Research Communications

Volumn 414, Issue 3, 2011, Pages 474-480

  Varga, Nóra ^a   Veréb, Zoltán ^b   Rajnavölgyi, Éva ^b   Német, Katalin ^a   Uher, Ferenc ^a   Sarkadi, Balázs ^a   Apáti, Ágota ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Feeder cell; Human embryonic stem cells; Immunosuppressive feature; Mesenchymal stem cell like (MSCl) cells

Indexed keywords

5' NUCLEOTIDASE; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CD14 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CELL SURFACE MARKER; ENDOGLIN; HERMES ANTIGEN; HLA DR ANTIGEN; OCTAMER TRANSCRIPTION FACTOR 4; STAGE SPECIFIC EMBRYO ANTIGEN 4; THY 1 ANTIGEN; TRANSCRIPTION FACTOR NANOG;

ADIPOGENESIS; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL LINE; CELL SURFACE; CHONDROGENESIS; EMBRYONIC STEM CELL; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; OSTEOBLAST; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADIPOGENESIS; BIOLOGICAL MARKERS; BIOTECHNOLOGY; CELL ADHESION; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL LINE; CHONDROGENESIS; EMBRYONIC STEM CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; MESENCHYMAL STEM CELLS; OSTEOGENESIS; PLURIPOTENT STEM CELLS;

EID: 80054955366     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.09.089     Document Type: Article

References (47)

1. Friedenstein A.J., Chailakhyan R.K., Latsinik N.V., et al. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues cloning in vitro and retransplantation in vivo. Transplantation 1974, 17:331-340.
2. Pittenger M.F., Mackay A.M., Beck S.C., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
3. Klyushnenkova E., Mosca J.D., Zernetkina V., et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J. Biomed. Sci. 2005, 12:47-57.
4. Kern S., Eichler H., Stoeve J., et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006, 24:1294-1301.
5. Grove J.E., Bruscia E., Krause D.S. Plasticity of bone marrow-derived stem cells. Stem Cells 2004, 22:487-500.
6. Ringden O., Uzunel M., Rasmusson I., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
7. Caplan A.I., Dennis J.E. Mesenchymal stem cells as trophic mediators. J. Cell Biochem. 2006, 98:1076-1084.
8. Philippe B., Luc S., Valerie P.B., et al. Culture and use of mesenchymal stromal cells in phase I and II clinical trials. Stem Cells Int. 2010, 503-593.
9. de Peppo G.M., Sjovall P., Lenneras M., et al. Osteogenic potential of human mesenchymal stem cells and human embryonic stem cell-derived mesodermal progenitors: a tissue engineering perspective. Tissue Eng. Part A 2010, 16:3413-3426.
10. Siddappa R., Licht R., van Blitterswijk C., et al. Donor variation and loss of multipotency during in vitro expansion of human mesenchymal stem cells for bone tissue engineering. J. Orthop. Res. 2007, 25:1029-1041.
11. Wang L., Tran I., Seshareddy K., et al. A comparison of human bone marrow-derived mesenchymal stem cells and human umbilical cord-derived mesenchymal stromal cells for cartilage tissue engineering. Tissue Eng. Part A 2009, 15:2259-2266.
12. Zhu Y., Liu T., Song K., et al. Adipose-derived stem cell: a better stem cell than BMSC. Cell Biochem. Funct. 2008, 26:664-675.
13. Cooper L.F., Zhou Y., Takebe J., et al. Fluoride modification effects on osteoblast behavior and bone formation at TiO2 grit-blasted c.p. titanium endosseous implants. Biomaterials 2006, 27:926-936.
14. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., et al. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282:1145-1147.
15. Itskovitz-Eldor J., Schuldiner M., Karsenti D., et al. Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol. Med. 2000, 6:88-95.
16. Murry C.E., Keller G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 2008, 132:661-680.
17. Lian Q., Lye E., Suan Yeo K., et al. Derivation of clinically compliant MSCs from CD105+, CD24- differentiated human ESCs. Stem Cells 2007, 25:425-436.
18. Liu Y.P., Hematti P. Generation of mesenchymal stromal cells from HOXB4-expressing human embryonic stem cells. Cytotherapy 2009, 11:716-725.
19. Olivier E.N., Rybicki A.C., Bouhassira E.E. Differentiation of human embryonic stem cells into bipotent mesenchymal stem cells. Stem Cells 2006, 24:1914-1922.
20. Trivedi P., Hematti P. Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells. Exp. Hematol. 2008, 36:350-359.
21. Apati A., Orban T.I., Varga N., et al. High level functional expression of the ABCG2 multidrug transporter in undifferentiated human embryonic stem cells. Biochim. Biophys. Acta 2008, 1778:2700-2709.
22. Pittenger M.F. Mesenchymal stem cells from adult bone marrow. Methods Mol. Biol. 2008, 449:27-44.
23. Schambach A., Galla M., Maetzig T., et al. Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol. Ther. 2007, 15:1167-1173.
24. Ujhelly O., Ozvegy C., Varady G., et al. Application of a human multidrug transporter (ABCG2) variant as selectable marker in gene transfer to progenitor cells. Hum. Gene. Ther. 2003, 14:403-412.
25. Stojkovic P., Lako M., Stewart R., et al. An autogeneic feeder cell system that efficiently supports growth of undifferentiated human embryonic stem cells. Stem Cells 2005, 23:306-314.
26. Wang Q., Fang Z.F., Jin F., et al. Derivation and growing human embryonic stem cells on feeders derived from themselves. Stem Cells 2005, 23:1221-1227.
27. Xu C., Jiang J., Sottile V., et al. Immortalized fibroblast-like cells derived from human embryonic stem cells support undifferentiated cell growth. Stem Cells 2004, 22:972-980.
28. Dominici M., Le Blanc K., Mueller I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006, 8:315-317.
29. Gimble J.M., Guilak F., Nuttall M.E., et al. In vitro differentiation potential of mesenchymal stem cells. Transfus. Med. Hemother. 2008, 35:228-238.
30. Tan Z., Su Z.Y., Wu R.R., et al. Immunomodulative effects of mesenchymal stem cells derived from human embryonic stem cells in vivo and in vitro. J. Zhejiang Univ. Sci. B 2011, 12:18-27.
31. Hoogduijn M.J., Popp F., Verbeek R., et al. The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. Int. Immunopharmacol 2010, 10:1496-1500.
32. Le Blanc K., Tammik L., Sundberg B., et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand. J. Immunol. 2003, 57:11-20.
33. H. Yagi, A. Soto-Gutierrez, B. Parekkadan, et al., Mesenchymal stem cells: Mechanisms of immunomodulation and homing, Cell Transplant., 19, 667-79.
34. Krampera M., Glennie S., Dyson J., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101:3722-3729.
35. Di Nicola M., Carlo-Stella C., Magni M., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
36. Rasmusson I., Ringden O., Sundberg B., et al. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp. Cell Res. 2005, 305:33-41.
37. E.J. Bassi, C.A. Aita, N.O. Camara, Immune regulatory properties of multipotent mesenchymal stromal cells: Where do we stand?, World J. Stem. Cells, 3, 1-8.
38. Nauta A.J., Fibbe W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007, 110:3499-3506.
39. C. Bouffi, C. Bony, G. Courties, et al., IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis, PLoS One, 5, e14247.
40. Djouad F., Charbonnier L.M., Bouffi C., et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007, 25:2025-2032.
41. Jarvinen L., Badri L., Wettlaufer S., et al. Lung resident mesenchymal stem cells isolated from human lung allografts inhibit T cell proliferation via a soluble mediator. J. Immunol. 2008, 181:4389-4396.
42. Najar M., Rouas R., Raicevic G., et al. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy 2009, 11:570-583.
43. Ryan J.M., Barry F., Murphy J.M., et al. but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin. Exp. Immunol. 2007, 149:353-363.
44. Nasef A., Chapel A., Mazurier C., et al. Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene. Expr. 2007, 13:217-226.
45. Yen B.L., Chang C.J., Liu K.J., et al. Brief report-human embryonic stem cell-derived mesenchymal progenitors possess strong immunosuppressive effects toward natural killer cells as well as T lymphocytes. Stem Cells 2009, 27:451-456.
46. Barberi T., Willis L.M., Socci N.D., et al. Derivation of multipotent mesenchymal precursors from human embryonic stem cells. PLoS Med. 2005, 2:e161.
47. Hwang N.S., Varghese S., Lee H.J., et al. In vivo commitment and functional tissue regeneration using human embryonic stem cell-derived mesenchymal cells. Proc. Natl. Acad. Sci. USA 2008, 105:20641-20646.